On August 14th, Gelonhui reported that Lionco Pharmaceutical Group (603669.SH), announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd. ("Lionco Pharmaceutical") has recently received the Approval Notice of Supplementary Application for Drug Approval ("the Notice") issued by the National Medical Products Administration (NMPA) for the drug, cefoperazone sodium for injection (the "Drug"). The Drug has passed the generic drug quality and efficacy consistency evaluation.
Cefoperazone sodium for injection is mainly used for: lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, pneumonia caused by streptococcus pneumoniae or influenza bacillus, and simple gonorrhea.
